BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37578441)

  • 21. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
    Yan X; Li G
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
    Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
    Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
    Wang H; Han Y
    Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs.
    Zhang Y; Feng YC; Zhu HG; Xiong TC; Hou YS; Song J; Jiang W; Zhu CJ
    Medicine (Baltimore); 2018 Jul; 97(30):e11648. PubMed ID: 30045314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
    Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of preoperative neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in the prognosis of resected early-stage patients with non-small cell lung cancer: A meta-analysis.
    Cao W; Yu H; Zhu S; Lei X; Li T; Ren F; Zhou N; Tang Q; Zu L; Xu S
    Cancer Med; 2023 Mar; 12(6):7065-7076. PubMed ID: 36480232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical value of neutrophil-to-lymphocyte ratio in patients with non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Jiang T; Bai Y; Zhou F; Li W; Gao G; Su C; Ren S; Chen X; Zhou C
    Lung Cancer; 2019 Apr; 130():76-83. PubMed ID: 30885355
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of peripheral neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio is predictive of pathological complete response after neoadjuvant chemotherapy in breast cancer patients.
    Graziano V; Grassadonia A; Iezzi L; Vici P; Pizzuti L; Barba M; Quinzii A; Camplese A; Di Marino P; Peri M; Veschi S; Alberti S; Gamucci T; Di Gioacchino M; De Tursi M; Natoli C; Tinari N
    Breast; 2019 Apr; 44():33-38. PubMed ID: 30611095
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.
    Suh KJ; Kim SH; Kim YJ; Kim M; Keam B; Kim TM; Kim DW; Heo DS; Lee JS
    Cancer Immunol Immunother; 2018 Mar; 67(3):459-470. PubMed ID: 29204702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
    Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
    Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor-infiltrating neutrophils and peripheral neutrophil-to-lymphocyte ratio conversely predicted the prognosis of patients with non-small cell lung cancer.
    Yang R; Wang X; Ma C; Zhang Z; Liu N; Ma X; Zhang Y; Wang X; Liu Y
    Cell Immunol; 2022 Sep; 379():104588. PubMed ID: 35961201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as Prognostic Factors in Locally Advanced Rectal Cancer.
    Duque-Santana V; López-Campos F; Martin-Martin M; Valero M; Zafra-Martín J; Couñago F; Sancho S
    Oncology; 2023; 101(6):349-357. PubMed ID: 36273439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic Relevance of Neutrophil to Lymphocyte Ratio (NLR) in Luminal Breast Cancer: A Retrospective Analysis in the Neoadjuvant Setting.
    Grassadonia A; Graziano V; Iezzi L; Vici P; Barba M; Pizzuti L; Cicero G; Krasniqi E; Mazzotta M; Marinelli D; Amodio A; Natoli C; Tinari N
    Cells; 2021 Jul; 10(7):. PubMed ID: 34359855
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 35. Prognostic Impact of Using Combined Plasma Fibrinogen Level and Neutrophil-to-Lymphocyte Ratio in Resectable Non-small Cell Lung Cancer.
    Iwasaki M; Ishihara S; Okada S; Shimegi R; Shimomura M; Inoue M
    Ann Surg Oncol; 2022 Sep; 29(9):5699-5707. PubMed ID: 35653068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery.
    Zhang Y; Wang L; Liu Y; Wang S; Shang P; Gao Y; Chen X
    Int J Gynecol Cancer; 2014 Sep; 24(7):1319-25. PubMed ID: 25033256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can the Neutrophil to Lymphocyte Ratio Predict Complete Pathologic Response to Neoadjuvant Breast Cancer Treatment? A Systematic Review and Meta-analysis.
    Cullinane C; Creavin B; O'Leary DP; O'Sullivan MJ; Kelly L; Redmond HP; Corrigan MA
    Clin Breast Cancer; 2020 Dec; 20(6):e675-e681. PubMed ID: 32653471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
    Rocha P; Zhang J; Laza-Briviesca R; Cruz-Bermúdez A; Bota-Rabassedas N; Sanchez-Espiridon B; Yoshimura K; Behrens C; Lu W; Tang X; Pataer A; Parra ER; Haymaker C; Fujimoto J; Swisher SG; Heymach JV; Gibbons DL; Lee JJ; Sepesi B; Cascone T; Solis LM; Provencio M; Wistuba II; Kadara H
    Clin Cancer Res; 2022 Jun; 28(11):2461-2473. PubMed ID: 35394499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
    Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
    BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Change in Neutrophil-to-Lymphocyte Ratio During Neoadjuvant Treatment Does Not Predict Pathological Response and Survival in Resectable Pancreatic Ductal Adenocarcinoma.
    Strong JS; Vos EL; Mcintyre CA; Chou JF; Gonen M; Tang LH; Soares KC; Balachandran VP; Kingham TP; D'Angelica MI; Jarnagin WR; Drebin J; Kunstman JW; Allen PJ; Wei AC
    Am Surg; 2022 Jun; 88(6):1153-1158. PubMed ID: 33517697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.